Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer.

Trial Profile

Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2016

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics
  • Acronyms SIGNAL
  • Most Recent Events

    • 27 Nov 2016 New trial record
    • 11 Oct 2016 Results evaluating the impact of HER expression levels in the PHARE/SIGNAL cohort (n=5474; HER2+) presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results of sequential vs concomitant incorporation of trastuzumab with chemotherapy in the PHARE/SIGNAL cohort (n=5502; HER2+) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top